Immunotherapy for SARS-CoV-2: potential opportunities
- 12 August 2020
- journal article
- editorial
- Published by Taylor & Francis Ltd in Expert Opinion on Biological Therapy
- Vol. 20 (10), 1111-1116
- https://doi.org/10.1080/14712598.2020.1807933
Abstract
(2020). Immunotherapy for SARS-CoV-2: potential opportunities. Expert Opinion on Biological Therapy. Ahead of Print.Keywords
Funding Information
- not funded
This publication has 48 references indexed in Scilit:
- Coronavirus Disease 2019 (COVID-19): A Perspective from ChinaRadiology, 2020
- U1 snRNP regulates cancer cell migration and invasion in vitroNature Communications, 2020
- DAMP-driven metabolic adaptationNature Reviews Immunology, 2019
- Myeloid immunosuppression and immune checkpoints in the tumor microenvironmentCellular & Molecular Immunology, 2019
- Commensal–Pathogen Interactions along the Human Nasal PassagesPLoS Pathogens, 2016
- IL‐6: Regulator of Treg/Th17 balanceEuropean Journal of Immunology, 2010
- The Molecular Biology of SARS CoronavirusAnnals of the New York Academy of Sciences, 2007
- Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike VariantsJournal of Virology, 2005
- Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2005
- Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor associationProceedings of the National Academy of Sciences of the United States of America, 2004